Avanir Pharmaceuticals Announces Three Poster Presentations at Consortium of MS Centers Meeting Including Preliminary …

ALISO VIEJO, Calif., June 1, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (AVNR) today announced the presentation of three posters, including preliminary results from the PRISM patient registry, at the Fourth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research in Multiple Sclerosis.

PRISM Registry

The aims of the PRISM registry are to define pseudobulbar affect (PBA) prevalence and its quality of life (QoL) impacton patients with the associated underlying neurologic conditions of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease, stroke, and traumatic brain injury (TBI).

Results

At the time of the data-cut a total of 3,647 patients with the six underlying neurologic conditions had enrolled in the PRISM registry. Among the enrolled patients, a total of 37.3% of all participants (n=1,361) had a positive screening score for PBA as measured by a CNS-LS13. The range of positive screening for PBA was similar across all the disease states (range of 34.7% to 40.0%); the prevalence of positive screens was also similar in the MS patient group (38.7%; n=354). The table below displays interim positive PBA screening rates of the current registry participants by underlying neurologic diagnosis. These prevalence rates of positive screens are similar to those seen in estimates previously published in the medical literature.

Underlying Disease or Injury

PRISM Results (CNS-LS13)

ALS

40.0%

Stroke

Continued here:
Avanir Pharmaceuticals Announces Three Poster Presentations at Consortium of MS Centers Meeting Including Preliminary ...